Page last updated: 2024-11-12

granite

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

granite: crystalline rock of quartz, orthoclase, muscovite & biotite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11784975
CHEMBL ID1895913
CHEBI ID81776
SCHEMBL ID116968
MeSH IDM0051343

Synonyms (47)

Synonym
NCGC00163715-01
granite
penoxsulam [iso]
2-(2,2-difluoroethyl)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide
219714-96-2
penoxsulam
NCGC00163715-02
NCGC00163715-03
C18481
dtxsid0034803 ,
dtxcid8014803
cas-219714-96-2
tox21_301010
NCGC00254912-01
784elc1scz ,
unii-784elc1scz
hsdb 7887
benzenesulfonamide, 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)-
CHEMBL1895913
chebi:81776 ,
3-(2,2-difluoroethoxy)-n-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-.alpha.,.alpha.,.alpha.-trifluorotoluene-2-sulfonamide
penoxsulam [mi]
2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide
viper
de-638
de 638
SCHEMBL116968
2-(2,2-difluoroethoxy)-6-trifluoromethyl-n-(5, 8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)benzenesulfonamide
2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]-triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide
2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide
AC-24494
FT-0696708
AKOS025401685
2-(2,2-difluoroethoxy)-n-{5,8-dimethoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl}-6-(trifluoromethyl)benzene-1-sulfonamide
penoxsulam, pestanal(r), analytical standard
penoxsulam 100 microg/ml in acetonitrile
BCP18718
Q22808507
pxd ,
2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)-6-(trifluoromethyl)benzenesulfonamide
AMY12535
C13421
2-(2,2-difluoroethoxy)--6-(trifluoromethyl-n-(5,8-dimethoxy
benzenesulfonamide, 2-(2,2-difluoroethoxy)-n-(5,8-dimethoxy
3-(2,2-difluoroethoxy)-n-(5,8-dimethoxy(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-alpha,alpha,alpha-trifluorotoluene-2-sulfonamide
granite8122
usepa/opp pesticide code: 119031

Research Excerpts

Overview

Granite is an igneous rock that contains natural radioactivity of primordial radionuclides. Granite can be used as a shielding material, for bulk in the form of the aggregate in concrete.

ExcerptReferenceRelevance
"Granite is a widely available rock, which can be used as a shielding material, for bulk in the form of the aggregate in concrete. "( RADIOLOGICAL IMPACT OF USING DECORATIVE GRANITE AS AN ATTENUATOR OF IONIZING RADIATION.
Hassan, NM; Lee, JB, 2023
)
2.62
"Granite is an igneous rock that contains natural radioactivity of primordial radionuclides. "( Radiological implications of granite of northern Pakistan.
Abid, A; Asghar, M; Tufail, M; Waqas, M, 2008
)
2.08

Toxicity

ExcerptReferenceRelevance
" Based on earlier studies, response levels were either intermediate between nontoxic iron oxide and toxic alpha-quartz or comparable with alpha-quartz."( The pulmonary toxicity of talc and granite dust as estimated from an in vivo hamster bioassay.
Beck, BD; Brain, JD; Feldman, HA; Gerson, B; Hallock, M; Smith, TJ, 1987
)
0.55

Dosage Studied

ExcerptRelevanceReference
" Dose-response (0."( The pulmonary toxicity of talc and granite dust as estimated from an in vivo hamster bioassay.
Beck, BD; Brain, JD; Feldman, HA; Gerson, B; Hallock, M; Smith, TJ, 1987
)
0.55
"Healthy worker selection bias is directly assessed by comparing the dose-response associations between survivors who remained in the study for the full 5-year observation period and the dropouts."( Healthy worker effect in a longitudinal study of one-second forced expiratory volume (FEV1) and chronic exposure to granite dust.
Eisen, EA; Louis, TA; Peters, JM; Smith, TJ; Wegman, DH, 1995
)
0.5
" The dose-response parameter in this group was estimated to be 4 ml/yr loss per mg/m3-year and was statistically significant."( Healthy worker effect in a longitudinal study of one-second forced expiratory volume (FEV1) and chronic exposure to granite dust.
Eisen, EA; Louis, TA; Peters, JM; Smith, TJ; Wegman, DH, 1995
)
0.5
"Despite loss in power and restricted exposure range, decreasing the relative proportion of prevalent to incident hires reduced HWSE bias, resulting in stronger evidence for a dose-response between silica exposure and lung cancer mortality."( Reducing healthy worker survivor bias by restricting date of hire in a cohort study of Vermont granite workers.
Applebaum, KM; Eisen, EA; Malloy, EJ, 2007
)
0.56
"001) with a trend toward dose-response excluding silicotics and controlling for tobacco."( High prevalence and advanced silicosis in active granite workers: a dose-response analysis including FEV1.
Cuervo, V; Dubois, A; Gil, M; González, A; Isidro, I; Martínez, C; Pichel, A; Quero, A; Rego, G, 2008
)
0.6
" Beyond 30% dosage of granite, tailings are not recommended as they may lead to the poor gradation of particles and weak bonding in the microstructure."( Synergistic effect on the performance of ash-based bricks with glass wastes and granite tailings along with strength prediction by adopting machine learning approach.
Chithra, S; Praburanganathan, S; Simha Reddy, YB, 2022
)
1.26
" Dose-response confirmed the detected resistances in the representative populations, and suggested that the majority of observed resistance was dose-dependent."( Target and nontarget mechanisms of AHAS inhibitor cross-resistance patterns in Cyperus difformis.
Al-Khatib, K; Ceseski, AR; Godar, AS; Ohadi, S, 2023
)
0.91
" The hazardous radiometric variables were computed, and the findings observed that the mean absorbed dosage was 23."( Natural Radioactivity of Granitic Rocks and Their Health Risk around Ingesana Mountains, Sudan.
Abdelrazig, A; Alashban, Y; Fadol, N; Idriss, H; Shubayr, N, 2024
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (5 Items)

ItemProcessFrequency
Gressinscore-ingredient1
Painscore-ingredient1
Céréales et pommes de terrecore-ingredient1
Aliments d'origine végétalecore-ingredient1
Aliments et boissons à base de végétauxcore-ingredient1

Drug Classes (1)

ClassDescription
triazolopyrimidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency27.00500.000214.376460.0339AID588532; AID588533
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.31600.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency48.96620.000229.305416,493.5996AID743069
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency54.94100.023723.228263.5986AID743222
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743066
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency43.27710.000627.21521,122.0200AID651741
Cellular tumor antigen p53Homo sapiens (human)Potency30.63790.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1111016Phytotoxicity against two to three-leaf stage indica Oryza sativa (rice) under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111014Post-emergence herbicidal activity against two to three-leaf stage Schoenoplectiella juncoides under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111017Post-emergence herbicidal activity against three-leaf stage Schoenoplectiella juncoides under field condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111010Post-emergence herbicidal activity against three to four-leaf stage Sesbania herbacea under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111043Post-emergence herbicidal activity against three-leaf stage Monochoria vaginalis under green-house condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111018Post-emergence herbicidal activity against three-leaf stage Monochoria vaginalis under field condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111020Post-emergence herbicidal activity against three-leaf stage Echinochloa crus-galli (barnyard grass) under field condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111023Post-emergence herbicidal activity against three-leaf stage Echinochloa crus-galli (barnyard grass) under green-house condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111015Post-emergence herbicidal activity against 2-3-leaf stage Echinochloa crus-galli (barnyard grass) under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111011Post-emergence herbicidal activity against 3-4-leaf stage Echinochloa crus-galli (barnyard grass) under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111021Post-emergence herbicidal activity against three-leaf stage Cyperus difformis under green-house condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111013Phytotoxicity against three to four-leaf stage japonica Oryza sativa (rice) under field condition by foliar application method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111022Post-emergence herbicidal activity against three-leaf stage Schoenoplectiella juncoides under green-house condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111019Phytotoxicity against three-leaf stage Oryza sativa (rice) under field condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
AID1111024Phytotoxicity against three-leaf stage Oryza sativa (rice) under green-house condition by water injection treatment method2009Bioorganic & medicinal chemistry, Jun-15, Volume: 17, Issue:12
Penoxsulam--structure-activity relationships of triazolopyrimidine sulfonamides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (375)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (5.33)18.7374
1990's19 (5.07)18.2507
2000's95 (25.33)29.6817
2010's158 (42.13)24.3611
2020's83 (22.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 98.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index98.49 (24.57)
Research Supply Index5.95 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index205.26 (26.88)
Search Engine Supply Index2.32 (0.95)

This Compound (98.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.31%)6.00%
Case Studies2 (0.52%)4.05%
Observational0 (0.00%)0.25%
Other375 (98.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]